25 235

Cited 0 times in

Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.

Choi, JH; Kim, HC; Lim, HY; Nam, DK; Kim, HS; Yi, JW; Chun, M; Oh, YT; Kang, S; Park, KJ; Hwang, SC; Lee, YH; Hahn, MH
Lung cancer (Amsterdam, Netherlands), 33(2-3):171-179, 2001
Journal Title
Lung cancer (Amsterdam, Netherlands)
BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide expressed in a wide variety of tumors, and it stimulates angiogenesis and increases vascular permeability. Increased expression of VEGF may be associated with advanced stage and poor prognosis in patients with non-small cell lung cancer (NSCLC).

METHODS: Using enzyme-linked immunosorbent assay, the levels of VEGF were determined in serum from 41 patients with untreated NSCLC (Stage: IIB, 3; IIIA, 6; IIIB, 17; IV, 15; Histology: squamous cell carcinoma, 18; adenocarcinoma. 14; undetermined, 9).

RESULTS: The median VEGF level was 312 pg/ml, ranging from 70 to 1440 pg/ml. Patients were divided into high VEGF (>312 pg/ml) and low VEGF (< or =312 pg/ml) groups using the median value as a cut-off. There were no significant associations between the serum VEGF levels and various clinicopathologic characteristics including age, gender, histologic type, stage and treatment. A significant positive correlation was found between serum VEGF levels and platelet counts (r=0.495; P=0.001). In addition, serum VEGF levels also correlated with leukocyte counts (r=0.478; P=0.002). In seven patients with measurement of follow-up serum VEGF levels at the end of treatment (chemotherapy and/or radiotherapy), the median serum VEGF level significantly decreased after the treatment (416 pg/ml; range, 96-812 pg/ml vs. 185 pg/ml; range, 49-487 pg/ml; P=0.028). However, the median platelet count (317,000/microl; range, 190,000-395,000/microl vs. 246,000/microl; range, 72,000-271,000/microl; P=0.028) and leukocyte count (10,000/microl; range, 8700-17,200/microl vs. 5100/microl; range, 3900-9500/microl; P=0.018) also decreased after the treatment. There was no statistically significant difference in the median survival of the patients between high VEGF group and low VEGF group (8 months vs. 9 months, P=0.647).

CONCLUSIONS: Although serum VEGF level was significantly associated with platelet and leukocyte counts in NSCLC patients, it did not correlate with tumor burden and prognosis of the patients.
MeSH terms
Adenocarcinoma/blood*Adenocarcinoma/therapyAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell Lung/blood*Carcinoma, Non-Small-Cell Lung/therapyCarcinoma, Squamous Cell/blood*Carcinoma, Squamous Cell/therapyEndothelial Growth Factors/blood*Enzyme-Linked Immunosorbent AssayFemaleHumansLeukocyte Count*Lung Neoplasms/blood*Lymphokines/blood*MaleMiddle AgedNeoplasm StagingPlatelet Count*PrognosisVascular Endothelial Growth Factor AVascular Endothelial Growth Factors
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
최, 진혁김, 효철임, 호영남, 동기김, 현수전, 미선오, 영택강, 승희박, 광주황, 성철이, 이형
Full Text Link
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.